News

BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC's Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation.

03/07/2025

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

KUALA LUMPUR, Malaysia, March 06, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in technology and healthcare, is pleased to announce that its Board of Directors has formally approved the Company's new Ethereum-focused treasury strategy. This decision marks BGLC as the first Nasdaq-listed company to exclusively prioritize Ethereum (ETH) as a strategic treasury asset, and is in line with recent announcements of Ethereum being included in the US “Crypto Strategic Reserve”.

03/05/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is BioNexus Gene Lab Corporation (BGLC) a buy, sell, or hold?

BioNexus Gene Lab Corporation (BGLC) can sell. Click on Rating Page for detail.

What is BioNexus Gene Lab Corporation's stock price?

The price of BioNexus Gene Lab Corporation (BGLC) is 0.26 and it was updated on 2025-04-02 13:00:21.

Is BioNexus Gene Lab Corporation (BGLC) overvalued or undervalued?

Currently BioNexus Gene Lab Corporation (BGLC) is in undervalued.

News

From:

To:

News
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Wed, Sep. 25, 2024
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd. KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. (“MRNA Scientific”), has entered into a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. (“Vitarray”), an exempted private company incorporated in Singapore. This agreement focuses on the provision of mRNA dynamic gene detection services for the Southeast Asian market. Fri, Sep. 13, 2024
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU) with Shenzhen Rongguang Health Group, a major healthcare services provider in China. This partnership aims to expand the Company's expertise and presence in cancer screening, precision medicine, and preventative healthcare through its subsidiary MRNA Scientific Sdn Bhd. Thu, Sep. 12, 2024
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximately RM 2 million (approx. USD $450,000) to begin the production of fine-quality color paste (non-drying type) specifically designed for composite industrial customers. The new production facility will commence operations in late September 2024, marking a significant milestone for the Company as it seeks to expand its portfolio and enhance its market presence globally. Wed, Sep. 11, 2024
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction and potential of AISB. Tue, Aug. 27, 2024

SEC Filings

SEC Filings
BioNexus Gene Lab Corporation (BGLC) - NT 10-K - Current report SEC Filings 03/31/2025
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 03/25/2025
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 03/07/2025
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 03/05/2025
BioNexus Gene Lab Corporation (BGLC) - DEFR14A SEC Filings 02/28/2025
BioNexus Gene Lab Corporation (BGLC) - DEF 14A SEC Filings 02/27/2025
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 02/14/2025
BioNexus Gene Lab Corporation (BGLC) - PRE 14A SEC Filings 02/10/2025
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 01/02/2025
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 11/15/2024
BioNexus Gene Lab Corporation (BGLC) - NT 10-Q - Quarterly Report SEC Filings 11/14/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 11/08/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 10/15/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 10/10/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 09/25/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 09/18/2024
BioNexus Gene Lab Corporation (BGLC) - DEF 14A SEC Filings 09/16/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 09/12/2024
BioNexus Gene Lab Corporation (BGLC) - PRE 14A SEC Filings 09/06/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 09/05/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 08/28/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 08/26/2024
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 08/14/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K/A - Current report SEC Filings 07/05/2024
BioNexus Gene Lab Corporation (BGLC) - 10-Q/A - Quarterly Report SEC Filings 05/31/2024
BioNexus Gene Lab Corporation (BGLC) - 10-K/A - Current report SEC Filings 05/31/2024
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 05/15/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 05/09/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 04/18/2024
BioNexus Gene Lab Corporation (BGLC) - 10-K - Current report SEC Filings 04/16/2024
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 04/01/2024
BioNexus Gene Lab Corporation (BGLC) - NT 10-K - Current report SEC Filings 03/28/2024
BioNexus Gene Lab Corporation (BGLC) - 10-Q/A - Quarterly Report SEC Filings 03/26/2024
BioNexus Gene Lab Corporation (BGLC) - DEF 14C SEC Filings 02/29/2024
BioNexus Gene Lab Corporation (BGLC) - PRE 14C SEC Filings 01/26/2024
BioNexus Gene Lab Corporation (BGLC) - SC 13G SEC Filings 01/23/2024
BioNexus Gene Lab Corporation (BGLC) - SC 13D SEC Filings 01/17/2024
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 11/20/2023
BioNexus Gene Lab Corporation (BGLC) - NT 10-Q - Quarterly Report SEC Filings 11/14/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 11/13/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 11/03/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K/A - Current report SEC Filings 10/30/2023
BioNexus Gene Lab Corporation (BGLC) - SC 13G SEC Filings 10/17/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 10/16/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 10/11/2023
BioNexus Gene Lab Corporation (BGLC) - 3 SEC Filings 10/04/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 09/07/2023
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 08/16/2023
BioNexus Gene Lab Corporation (BGLC) - NT 10-Q - Quarterly Report SEC Filings 08/14/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 07/24/2023
BioNexus Gene Lab Corporation (BGLC) - 424B4 SEC Filings 07/21/2023
BioNexus Gene Lab Corporation (BGLC) - EFFECT SEC Filings 07/20/2023
BioNexus Gene Lab Corporation (BGLC) - CERT SEC Filings 07/20/2023
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 07/20/2023
BioNexus Gene Lab Corporation (BGLC) - 8-A12B SEC Filings 07/19/2023
BioNexus Gene Lab Corporation (BGLC) - S-1/A SEC Filings 07/17/2023
BioNexus Gene Lab Corporation (BGLC) - S-1/A SEC Filings 07/05/2023
BioNexus Gene Lab Corporation (BGLC) - DEF 14C SEC Filings 05/17/2023
BioNexus Gene Lab Corporation (BGLC) - S-1/A SEC Filings 05/09/2023
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 05/09/2023
BioNexus Gene Lab Corporation (BGLC) - 10-K - Current report SEC Filings 03/31/2023
BioNexus Gene Lab Corporation (BGLC) - DEFR14C SEC Filings 03/10/2023
BioNexus Gene Lab Corporation (BGLC) - DEF 14C SEC Filings 02/21/2023
BioNexus Gene Lab Corporation (BGLC) - S-1 SEC Filings 02/14/2023
BioNexus Gene Lab Corporation (BGLC) - PRE 14C SEC Filings 02/10/2023
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 11/14/2022
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 08/15/2022
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 08/15/2022
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 05/16/2022
BioNexus Gene Lab Corporation (BGLC) - 10-K - Current report SEC Filings 04/06/2022
BioNexus Gene Lab Corporation (BGLC) - NT 10-K - Current report SEC Filings 04/01/2022
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 11/15/2021
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 08/12/2021
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 05/18/2021
BioNexus Gene Lab Corporation (BGLC) - NT 10-Q - Quarterly Report SEC Filings 05/17/2021
BioNexus Gene Lab Corporation (BGLC) - 10-K - Current report SEC Filings 03/30/2021
BioNexus Gene Lab Corporation (BGLC) - 8-K/A - Current report SEC Filings 03/11/2021
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 01/07/2021
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 12/30/2020
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 12/22/2020
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 12/10/2020
BioNexus Gene Lab Corporation (BGLC) - 10-Q/A - Quarterly Report SEC Filings 11/09/2020
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 11/03/2020
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 10/08/2020
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 08/11/2020
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 05/08/2020
BioNexus Gene Lab Corporation (BGLC) - 10-K - Current report SEC Filings 03/31/2020
BioNexus Gene Lab Corporation (BGLC) - NT 10-K - Current report SEC Filings 03/30/2020
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 11/14/2019
BioNexus Gene Lab Corporation (BGLC) - 8-K - Current report SEC Filings 10/15/2019
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 08/09/2019
BioNexus Gene Lab Corporation (BGLC) - 10-Q - Quarterly Report SEC Filings 05/15/2019
BioNexus Gene Lab Corporation (BGLC) - EFFECT SEC Filings 04/04/2019
BioNexus Gene Lab Corporation (BGLC) - EFFECT SEC Filings 04/03/2019
BioNexus Gene Lab Corporation (BGLC) - CORRESP SEC Filings 04/02/2019
BioNexus Gene Lab Corporation (BGLC) - S-1/A SEC Filings 03/27/2019
BioNexus Gene Lab Corporation (BGLC) - UPLOAD SEC Filings 03/04/2019
BioNexus Gene Lab Corporation (BGLC) - S-1/A SEC Filings 02/25/2019
BioNexus Gene Lab Corporation (BGLC) - UPLOAD SEC Filings 02/19/2019
BioNexus Gene Lab Corporation (BGLC) - S-1 SEC Filings 01/29/2019

Press Releases

StockPrice Release
Bionexus gene lab corp and ml tech partner to enhance ethereum-focused treasury strategy 03/07/2025
Bionexus gene lab corp. announces board approval of ethereum treasury strategy and release of strategic whitepaper 03/05/2025
Bionexus gene lab corporation announces entry into biogas sector via teaming agreement with protech builders sdn. bhd. 09/25/2024
Bionexus gene lab corp. signs strategic outsourcing agreement with vitarray global pte. ltd. 09/13/2024
Bionexus gene lab corp. signs strategic partnership mou with shenzhen rongguang group to advance cancer screening, precision medicine, and preventative healthcare solutions 09/12/2024
Bionexus gene lab corp announces new business developments for subsidiary chemrex with investment in high-quality color paste production 09/11/2024
Bionexus gene lab corp. announces successful securities commission of malaysia (mycif) co-investment in ascension innovation sdn bhd 08/27/2024
Bionexus gene lab corp. completes strategic rm 1 million investment in ascension innovation sdn bhd 08/26/2024
Bionexus gene lab corp. agrees to invest rm 1.2 million in ascension innovation (aisb) to advance digital health innovation through ai adoption in healthcare 04/18/2024
Bionexus gene lab corp. announces closing of $5.75 million public offering and full exercise of over-allotment option and uplisting to the nasdaq capital market 07/24/2023
Bionexus gene lab corp. announces pricing of $5 million public offering and uplisting to the nasdaq capital market 07/20/2023

More Headlines

News
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC's wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC's commitment to advancing AI-driven healthcare solutions. 08/26/2024
Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today? BioNexus Gene Lab (NASDAQ: BGLC ) stock is falling on Friday but investors will note that this comes after its shares underwent a rally late on Thursday. BioNexus Gene Lab shares closed out Thursday up 28.8% with about 3.1 million units traded. 04/19/2024
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare KUALA LUMPUR, Malaysia, April 19, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ: BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics. 04/18/2024
Why Is BioNexus (BGLC) Stock Up 323% Today? BioNexus (NASDAQ: BGLC ) stock is rocketing higher on Tuesday despite a lack of news concerning the chemical raw material products company. Instead, traders are seeing shares of BGLC stock rally this morning alongside heavy trading. 02/13/2024
Why Is BioNexus Gene Lab (BGLC) Stock Up 33% Today? BioNexus Gene Lab (NASDAQ: BGLC ) stock is rising higher on Wednesday despite a lack of news concerning the chemical raw material company. There haven't been any new press releases that explain why BGLC stock is up today. 08/23/2023
BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market KUALA LUMPUR, Malaysia, July 24, 2023 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BioNexus” or the “Company”) (Nasdaq: BGLC), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis and personalized health management, today announced the closing of an underwritten public offering (the “Offering”) of 1,437,500 shares of common stock, including 187,500 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The Offering was priced at $4.00 per share for total gross proceeds of $5.75 million before deducting underwriting discounts and commissions and offering expense. 07/24/2023
Why Is BioNexus Gene Lab (BGLC) Stock Up 64% Today? BioNexus Gene Lab (NASDAQ: BGLC ) stock is taking off on Friday after the company uplisted its shares to the Nasdaq Capital Market. That saw the company's shares start trading on the Nasdaq Capital Market yesterday. 07/21/2023

Unlock

BGLC Ratings Summary

BGLC Quant Ranking

Is BioNexus Gene Lab Corporation (BGLC) a buy, sell, or hold?

What is BioNexus Gene Lab Corporation's stock price?

Is BioNexus Gene Lab Corporation (BGLC) overvalued or undervalued?

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today?

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

Why Is BioNexus (BGLC) Stock Up 323% Today?

Why Is BioNexus Gene Lab (BGLC) Stock Up 33% Today?

BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market

Why Is BioNexus Gene Lab (BGLC) Stock Up 64% Today?

Company Details

Ratings

Quant Factor Grades